Table 1.
Survival by MGMT methylation status in recent phase III trials for newly diagnosed glioblastoma
| Trial | MGMT Status | OS Median (95% CI) | PFS Median (95% CI) |
|---|---|---|---|
| EORTC 26981/22981 and NCIC trial CE.3a, 69,141 | Unmethylated | 12.6 (11.6–14.4) | 5.3 (not reported) |
| Methylated | 23.4 (18.6–32.8) | 10.9 (not reported) | |
| RTOG 052585 | Unmethylated | 14.0 (12.9–14.7) | 5.7 (5.1–6.1) |
| Methylated | 21.2 (17.9–24.8) | 8.7 (6.6–11.2) | |
| RTOG 082598 | Unmethylated | 14.3 (13.6–15.3) | 8.2 (7.5–9.2) |
| Methylated | 23.2 (20.1–28.3) | 14.1 (10.5–16.1) |
aOS statistics from Stupp Lancet Oncology 2009; PFS statistics from Hegi NEJM 2005. All statistics regard the RT + TMZ trial arm.
Abbreviations: MGMT, O(6)-methylguanine-DNA methyltransferase; OS, overall survival; PFS, progression-free survival; EORTC, European Organisation for Research and Treatment of Cancer; NCIC, National Cancer Institute of Canada; RTOG, Radiation Therapy Oncology Group.